Boan Biotech Partners with CP Qingdao to Accelerate the Commercialization of Boyoubei® in China

Yantai, January 10, 2023 —— Luye Pharma Group today announced that its subsidiary Boan Biotech has signed an agreement with CP Pharmaceutical Qingdao Co., Ltd. (CP Qingdao), to grant the latter the ...

Boan Biotech’s First Investigational ADC, BA1301 for Injection, Approved for Clinical Trials in China

January 09, 2023 - Luye Pharma Group announced today that BA1301 for injection, an innovative antibody-drug conjugate (ADC) candidate developed by its subsidiary Boan Biotech, has been approved for cl...

Voluntary Announcement Approval Obtained for Initiating Clinical Trial for the Innovative ADC Candidate BA1301 for Injection in China

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022

Boan Biotech Officially Listed on the Main Board of SEHK Accelerating to Become a Leading Global Biopharmaceutical Company

(30 December 2022, Hong Kong, China) Shandong Boan Biotechnology Co., Ltd. (“Boan Biotech” or the “Company”), a subsidiary of Luye Pharma Group, was officially listed on the Main Board of the Stoc...

Procedures for Shareholders to Propose a Person other than a Retiring Director for Election as a Director

Terms of Reference of the Audit Committee

Terms of Reference of the Nomination Committee

Terms of Reference of the Remuneration Committee

Terms of Reference of the Strategy Committee